Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKX101 in R/R AML and MDS
NCT04623944Phase 1Active, not recruiting
- Sponsor
- Nkarta
- Start
- Sep 2020
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NKX101 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Nkarta. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Response rate to NKX101. Started Sep 2020; status: active, not recruiting.
02
Drugs
NKX101
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04623944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623944.